Icon Group’s chemotherapy compounding services are delivered by Slade Health – a nearly 60 year strong pharmacy, hospital and aged care industry provider founded on a commitment to patient care, quality, innovation and integrity. The business operates a quality network of TGA-licensed manufacturing facilities across Australia in Brisbane, Sydney, Melbourne and Adelaide. In 2018, all of these facilities delivered building works to increase capacity.
Through a strategic focus on growth via contract and business acquisition, Slade Health has more than tripled its output from 300,000 to over 1,000,000 infusions annually since 2016, cementing its position as Australia’s leading chemotherapy compounders. The business currently holds contracts with two Australian State governments for the supply of chemotherapy products throughout their state health services, in addition to holding partial supply contracts with the governments of other Australian states.
